The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Journal club: STEP-HFpEF and symptom endpoints

This is a generated summary. It shows the 5 most-liked posts from a topic of 23, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
MR
m.radichTL229 Aug 2025#1

Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable.

The question about step-hfpef and symptom endpoints that I actually want answered is the second one below. The first is context and I have kept it short.

Both are stated with units, and I have said what I already checked so that nobody repeats it.

47 likes 11mo
SC
s.cardosoTL21 Sep 2025#6
m.radich, post #1: Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. The question about step-hfpef and symptom endpoints that I actually want answered is the second one below. The first is context and I have kept it short. Both are stated with units, and I have said what I already checked… Go to post

This follows post #3 rather than contradicting it.

On step-hfpef and symptom endpoints the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.

17 likes in reply to #1 11mo
CR
crossover_reviewTL3Regular4 Sep 2025#14
m.yilmaz, post #8: The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. Noting that the question and the thing people usually mean by it are different. Go to post

Coming back to post #10, because the follow-up matters more than the original answer.

Adding what did not work for me on step-hfpef and symptom endpoints, since the failures never get written up and they are half the useful information.

28 likes in reply to #8 11mo
MG
m.guerreroTL25 Sep 2025 · edited#17

Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.

It took me longer than it should have to see that.

19 likes 11mo
RS
r.serranoTL27 Sep 2025#21

Quietly grateful for the plain phrasing. Not every thread gets that.

15 likes 11mo

Read the full topic (23 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Posting a small dataset on STEP 8. It is…
OLIADSRFDO+18 22 656 13h
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
VKJBFNAITH 4 1.3k 1mo
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold?
The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. Reading SUSTAIN 6 ( N Engl J Med ,…
RONSPPSDOB+60 66 12k 16mo
[2026 update] Journal club: what we got wrong in an earlier session
Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. Bringing a claim rather than a paper, because the claim is the thing circulating.…
NVAVRJVBV+5 9 4.2k 1d
Journal club: the CagriSema phase 2 combination paper — a second dataset
Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on CagriSema phase 2 combination paper.…
ADACLMAK+74 79 2.3k 13mo

Related topics — sharing the tags journal club, effect size, estimand

TopicParticipantsRepliesViewsActivity
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
EHSBBOARB+3 7 1k 2mo
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest
Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
BAIDO 2 23k 21mo
Second pass at: Regression to the mean in progress reports
Second pass at: Regression to the mean in progress reports Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Regression. It is mine, it is…
SGCKIAMDM+71 75 4k 17mo
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…
TKJEPPSDPN+61 65 1.3k 22mo
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…
DPSGRIEDMB+80 91 10k 11mo